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Abstract
Background: Myelinoclastic diffuse sclerosis (MDS; also termed Schilder’s disease) is a rare inflammatory
demyelinating disorder of the central nervous system characterised by demyelination of vast areas of the white
matter. It is unclear whether MDS is a variant of multiple sclerosis (MS) or a disease entity in its own right.
Objective: To compare the cerebrospinal fluid (CSF) features of MDS with those of MS.
Methods: Retrospective analysis of the CSF profile of all patients with MDS reported in the medical literature
between 1960 and 2018.
Results: The most striking finding was a substantial lack of oligoclonal bands (OCBs) in MDS, which were absent in at
least 77% (30/39) of all lumbar punctures (LP) in the total cohort and in 86% in the subgroup of patients with normal
very long-chain fatty acid serum ratios (VLCFA). Almost all cases published in the past 15 years were negative for OCBs.
These findings are in contrast to MS, in which OCBs are present in up to 98% of cases (p < 0.00001 when compared
with reference works in MS; both in adult and in pediatric patients). CSF pleocytosis was absent in at least 79% (46/58)
of all LP (p < 0.0001 vs. MS) and in 92% (24/26) of LPs in the VLCFA-tested subgroup. CSF total protein levels were
elevated in 56% of all LPs (p < 0.0001 vs. MS) and in 63% of LPs in the VLCFA-tested subgroup and were often higher
than in typical MS (> 100mg/dL in 13/22; up to 220mg/dL). EBV serum antibodies, which are present in virtually all
patients with MS, and the so-called MRZ (measles/rubella/zoster) reaction, a highly specific marker of MS, were absent
in all of the few patients tested. In addition, we discuss further differences between MS and MDS, taking into account
also Schilder’s original comprehensive case description from 1912.
Conclusion: In the majority of patients diagnosed with MDS, CSF features differ significantly from those typically found
in MS and are more similar to those previously reported in patients with myelin oligodendrocyte glycoprotein-
immunoglobulin G (IgG)-positive encephalomyelitis, aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders
or Baló’s concentric sclerosis. Our data suggest that MDS and MS are immunopathologically distinct entities in the
majority of cases.
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Background
Myelinoclastic diffuse sclerosis (MDS; also termed Schilder’s
disease or encephalitis periaxialis diffusa) was first described
in 1912 by the Austrian psychiatrist Paul Ferdinand Schilder
(1886–1940) [1]. MDS is characterized by one or two exten-
sive, often bilateral and roughly symmetrical demyelinating
white matter lesions in the centrum semiovale. However, its
exact nosological relationship to multiple sclerosis (MS) has
remained elusive.
In a number of recent studies, we have demonstrated sub-
stantial differences in cerebrospinal fluid (CSF) features
between patients with MS and patients with other auto-
immune disorders of the central nervous system (CNS). In
particular, we have found significantly lower frequencies of
CSF-restricted oligoclonal bands (OCBs) and other markers
of intrathecal immunoglobulin G (IgG) synthesis in patients
with aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica
(NMO) spectrum disorders (NMOSD), myelin oligodendro-
cyte glycoprotein antibody-associated encephalomyelitis
(MOG-EM), acute demyelinating encephalomyelitis (ADEM)
and paraneoplastic neurological disorders (PND) than in MS,
as well as significant differences in intrathecal IgG compos-
ition and dynamics and in blood–CSF barrier function [2–
13]. This indicates that studying CSF profiles may be helpful
in distinguishing clinically related but immunopathogeneti-
cally distinct diseases.
To address the question of whether MDS is just a very
active and tumefactive variant of MS or an immuno-
logically distinct disease entity, we set out to systematic-
ally compare the CSF features of MDS with those of MS.
Methods
We performed a systematic review of all MDS cases
published in English, German, French or Spanish in
journals indexed in the PubMed database of the US Li-
brary of Science at the US National Institutes of Health
between January 1960 and December 2018. Relevant
publications were identified using the following search
expression: (“Schilder” OR “Schilder’s” OR “myelinoclas-
tic diffuse sclerosis” OR “diffuse myelinoclastic sclerosis”
OR “periaxialis diffusa”) NOT Schilder[author]. Further
papers were identified from the references lists of the
papers retrieved. Exclusion criteria were a diagnosis of
subacute sclerosing panencephalitis (SSPE), a diagnosis of ad-
renoleukodystrophy (ALD), abnormal very long-chain fatty
acid (VLCFA) serum test results, abnormal adrenal function
tests or familial CNS demyelination. Overall, we identified re-
ports on 92 lumbar punctures in 66 individual patients.
The parameters assessed included, alongside epidemio-
logical and clinical data, the presence or absence of
CSF-restricted OCBs; OCB patterns; CSF IgG concentra-
tion and CSF/serum ratio (QIgG); Link’s IgG index ([IgG
CSF/IgG serum]/[albumin CSF/albumin serum]); CSF
white cell count; CSF cytology; CSF gamma-globulin
fraction (γGF; as % of total CSF protein); measles/rubella/
zoster (MRZ) reaction, as defined by a positive reaction to
at least two of the three viral agents; CSF total protein (TP),
glucose and lactate concentrations; CSF myelin basic pro-
tein (MBP) concentrations; CSF opening pressure; Epstein–
Barr virus (EBV) and tuberculosis status; aquaporin-4
(AQP4) and myelin oligodendrocyte glycoprotein (MOG)
antibody serostatus; VLCFA serum ratio; and adrenal func-
tion test results.
A CSF white cell count > 5/μl was classified as in-
creased. An age-dependent upper reference range for
CSF L-lactate was applied (0–15 years of age, 1.8 mmol/
l; 16–50, 2.1 mmol/l; > 50, 2.6 mmol/l). The upper refer-
ence limit for CSF TP was set at 45 mg/dl, for CSF IgG
at 6 mg/dL, for IgG index at 0.7, for γGF at 13% [14], for
CSF glucose at 50% of serum glucose or 80 mg/dl and
for CSF opening pressure at 250 mmH2O.
Subgroup analyses were performed for patients ≥ 18 years
of age at onset (adult onset subgroup), patients < 18 years of
age at onset (non-adult onset subgroup) and patients with
available VLCFA results. Data from the MDS cohort were
compared to publicly available data from the MSBase registry
[15] and to data from reference studies in MS [16–21]. Dif-
ferences in frequency distributions among groups were stud-
ied using Fisher’s exact test. Due to the exploratory nature of
this study, no corrections for multiple testing were made. All
analyses were performed retrospectively; accordingly, no CSF
or serum samples were obtained for this study.
Results
Patient characteristics
The sex ratio (male:female) was 1:1.13, which is slightly
lower than that in classic MS according to data from the
MSBase registry [15] (1:2.39; N = 61,889). The median
age at onset was 12 years (range 2–69) in the total co-
hort, 17 years (range 6–69) among females (N = 35) and
10 (range 2–45) among males (N = 31). This is in contrast
to classic MS, in which the median age of onset is around
30 years (MSBase registry [15]; N = 61,889; p < 0.00001).
The patient’s genetic background was not specified in most
cases. Patients were reported by authors affiliated to centres
in Europe (N = 34; Austria, France, Germany, Hungary,
Italy, Poland, the Netherlands, Spain, UK), North America
(N = 12; Canada, USA), the Middle East (N = 9; Iran, Israel,
Turkey), the Far East (N = 3; China, Japan), South America
(N = 1; Brazil) and Australia (N = 1). Further patients were
of African (4 × South African, 1 ×Moroccan) and Jewish
(1 ×) descent. Exact data on the timing of lumbar puncture
(LP) was insufficient or missing in most reports. However,
LP was explicitly carried out after immunotherapy in only
1/82 (1.2%; no exact data in 10) and was performed during
phases of active disease in at least 62/70 (88.6%; no exact
data in 22). The disease course was described in most cases
but not defined consistently across the various studies. At
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last follow-up, only a single (though often prolonged)
attack had occurred in 26 patients; 24 had suffered
two or more distinguishable episodes (median 3); and
11 had experienced progressive and continued deteri-
oration. Median disease duration at last follow-up was
29 months (range 1–288).
Oligoclonal IgG bands
OCBs were present in only 23% of all LPs (N = 39) tested
for that marker and, at least once, in 26% of all patients
tested (N= 35) (Table 1). The frequency of OCBs was
slightly lower in the adult onset subgroup (18%; N = 11)
than in the childhood onset subgroup (29%; N = 24), but
the difference did not reach statistical significance (p= 0.65).
This contrasts with a frequency of OCBs of 98% in adult
MS and of 92% in childhood MS in two reference studies
(N = 267 [17] and 136 [16], respectively) (p < 0.0001 and
p < 0.0001; Fisher’s exact test, 2-tailed).
If only patients in whom ADL was excluded by a nega-
tive VLCFA test result are considered ('high diagnostic
certainty subgroup'), the frequency of CSF-restricted
OCBs was as low as 14% (4/28). When applying even
stricter criteria by taking into account only cases in
which both VLCFA and adrenal function test results
were available and normal, no patient had OCBs.
Of the few patients (N = 12) in whom an inflammatory
disease was suspected but ALD not excluded (no VLCFA
and no adrenal test results available) and in whom nei-
ther female gender nor favourable outcome argued
against ALD ('ALD risk group'), none had been tested
for OCBs. In consequence, these patients were not con-
sidered when calculating OCB rates. Therefore, acciden-
tal inclusion of patients with ALD is unlikely to have
contributed greatly to the low rate of OCBs in MDS ob-
served in this study.
In some case reports, CSF was classified as “normal” (or
“otherwise normal” if reporting was limited to pathological
items) but it was not specified whether OCBs were tested
or not. Given that OCBs are included in both the Poser
criteria for MS and the 1999, 2001 and 2017 McDonald
criteria for MS and are therefore more or less routinely
tested in patients presenting with CNS demyelination, it is
likely that some of the CSF samples classified as “normal”
or “otherwise normal” were tested also for OCBs. This
would imply that the true frequency of OCBs was even
lower than calculated from the available data. Assuming
OCB negativity in the samples that were classified as
“normal” or “otherwise normal” and tested since inclusion
of OCBs in the diagnostic criteria for MS in 1983, the
OCB rate would be as low as 17.6% in the total cohort
and 10.5% among VLCAF-tested patients.
Almost all positive OCB results were obtained be-
tween 1983 and 2003; only a single patient tested be-
tween 2004 and 2018 (N = 11) was positive for OCBs.
This argues strongly against lower sensitivity of isoelectric
focusing or OCB staining methods in the past accounting
for the low rate of OCBs in MDS in the literature.
CSF white cell counts
CSF white cell counts (WCC) were elevated in only 21%
(12/58) of all LPs and in only 24% (10/41) of all patients
(Table 1). They were particularly low in the pediatric
subgroup, in which pleocytosis was found in only 10%
(3/30) of all samples and, at least once, in 12% (3/25) of
all patients. This contrasts with a pleocytosis rate of over
50% in patients with MS (p < 0.0002 vs. [18]). The me-
dian WCC in CSF samples with pleocytosis and available
data was 25 cells/μl (range 11–277; N = 11; < 40 in 10/11
[90.9%]. Cytology results were reported for 9/12 patients
with pleocytosis; only lymphocytes were found in five of
those cases; lymphocytes and monocytes in one; lym-
phocytes and less than 20% granulocytes in one; and
predominantly polymorphonuclear cells in the only pa-
tient with more than 40 cells/μl.
In the subgroup of patients who were tested for VLCFA
('high diagnostic accuracy subgroup'), pleocytosis was
noted with only 8% (2/26) of the LPs. Of particular note,
CSF pleocytosis was absent in all LPs from VLCFA-tested
patients in the childhood onset subgroup (N = 16).
In some reports, LP findings were classified as “nor-
mal” or “otherwise normal” by the authors. Given that
WCC assessment is usually done in patients undergoing
LP, the true frequency of pleocytosis may thus be even
lower. Assuming that WCC was normal in those in-
stances, the rate of LPs with pleocytosis was just 5% in
the VLCFA-tested subgroup.
CSF total protein, lactate and glucose
Elevated CSF TP levels were present in at least 28/64 (44%)
of all LPs with available data and at least once in 23/47
(49%) patients, with no marked difference between adults
(13/28; 46%) and children (15/36; 42%) (Table 1). This con-
trasts with a TP elevation rate of 23.3% in 407 patients with
MS as observed in a recent study [19] (p < 0.0001).
The median TP concentration in patients with patho-
logical values was 114 mg/dL (range 46–220; N = 22; no
exact data available in 6 cases), and TP values exceeded
100 mg/dL in 13/22 (59%). By contrast, TP levels over
100 mg/dL are rare and, according to a consensus paper,
should prompt a search for alternative diagnoses in pa-
tients with suspected MS [20]. Similarly, the maximum
TP concentration observed in a cohort of 111 paediatric
MS patients was just 72 mg/dL.
CSF lactate levels were reported in only 7 patients and
were normal in all. CSF glucose levels were reported for 20
LPs in 18 patients and were slightly elevated in 2; a de-
crease in CSF glucose was reported in none of the patients.
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MRZ reaction, EBV and tuberculosis
The MRZ reaction was tested in five LPs from four pa-
tients diagnosed with MDS and was negative in all. In
one other case, CSF and serum antibodies to measles
and rubella were “not elevated”; in two additional cases,
antibodies to measles were absent or “present only at
low titer”, respectively, in CSF and serum; and in two
further patients, “serological titers to all common vi-
ruses” or “against neurotropic viruses”, respectively, were
negative. Finally, one patient had CSF antibodies to mea-
sles and varicella zoster virus, but it is unclear from the
report whether the antibody was produced intrathecally
(as required for diagnosing a positive MRZ reaction) or
had entered the CSF from the periphery (as is the case
also in healthy individuals).
Serum antibodies to EBV, which are present in virtu-
ally all patients with MS, were tested in at least five pa-
tients and were negative in all.
Table 1 Age and sex distribution, CSF OCB positivity rates, CSF WCC, CSF TP and CSF glucose and lactate in patients diagnosed
with MDS. §Assuming that the respective parameter was normal in samples classified as “normal” or “otherwise normal” (see the
“Results” section for details). Abbreviations: CSF cerebrospinal fluid, LP lumbar puncture, MDS myelinoclastic diffuse sclerosis, OCB
oligoclonal bands, TP total protein, WCC white cell count
Total cohort VLCFA-tested subgroup (VLCFA normal in all)
All Adult-onset Childhood-onset All Adult-onset Childhood-onset
Sex ratio, male:female 1:1.13 1:2.67 1:0.76 1:1.17 1:2.33 1:1
Age at onset, median (range),
years
12 (2–69) 29 (18–69) 9 (2–17) 10.5 (3–50) 32.5 (20–50) 8.5 (3–17)
OCB, positive, all LPs 23.1% (9/39) 15.4% (2/13) 26.9% (7/26) 14.3% (4/28) 0% (0/10) 22.2% (4/18)
OCB, positive, all LPs, including
LPs classified as “normal” (1983–)
17.6% (9/51) 0% (2/18) 0% (7/33) 10.5% (4/38) 0% (0/14) 16.6% (4/24)
OCB, positive, first LP 21.9% (7/32) 10% (1/10) 27.3% (6/22) 13.6% (3/22) 0% (0/8) 21.4% (3/14)
OCB, positive, patients 25.7% (9/35) 18.2% (2/11) 29.2% (7/24) 16.7% (4/24) 0% (0/8) 25% (4/16)
WCC, elevated, all LPs 20.7% (12/58) 32.1% (9/28) 10% (3/30) 7.7% (2/26) 20% (2/10) 0% (0/16)
WCC, elevated, all LPs, including
LPs classified as “normal”
15.2% (12/79) 26.5% (9/34) 6.7% (3/45) 4.9% (2/41) 14.3% (2/14) 0% (0/27)
WCC, elevated, first LP 25% (10/40) 43.8% (7/16) 12.5% (3/24) 10.5% (2/19) 28.6% (2/7) 0% (0/12)
WCC, elevated, patients 24.4% (10/41) 43.8% (7/16) 12% (3/25) 10.5% (2/19) 28.6% (2/7) 0% (0/12)
WCC, elevated, median (range),
all LPs
25 (11–277; N = 11) 24 (12–277; N = 8) 32 (11–36; N = 3) 150 (23–277; N = 2) 150 (23–277; N = 2) N.a. (N.a.; N = 0)
WCC, elevated, median (range),
first LPs
25 (11–277; N = 9) 24 (12–277; N = 6) 32 (11–36; N = 3) 150 (23–277; N = 2) 150 (23–277; N = 2) N.a. (N.a.; N=0)
WCC, elevated, median (range),
patients
25 (11–277; N = 9) 25 (15–277; N = 6) 32 (11–36; N = 3) 150 (23–277; N = 2) 150 (23–277; N = 2) N.a. (N.a.; N=0)
TP, elevated, all LPs 43.8% (28/64) 46.4% (13/28) 41.7% (15/36) 37.5% (12/32) 40% (4/10) 36.4% (8/22)
TP, elevated, all LPs, including
LPs classified as “normal”
32.9% (28/85) 38.2% (13/34) 29.4% (15/51) 26.1% (12/46) 28.6% (4/14) 25% (8/32)
TP, elevated, first LP 43.8% (28/64) 46.4% (13/28) 41.7% (15/36) 37.5% (12/32) 40% (4/10) 36.4% (8/22)
TP, elevated, patients 41.3% (19/46) 43.8% (7/16) 40% (12/30) 37.5% (9/24) 42.9% (3/7) 35.3% (6/17)
TP, elevated, median (range),
all LPs
114 (46–220;
N = 22)
135 (46–182;
N = 11)
112 (56–220;
N = 11)
103 (46–212; N = 7) 105.5 (46–165;
N = 2)
103 (56–212;
N = 5)
TP, elevated, median (range),
first LPs
116 (46–220;
N = 15)
97.5 (46–180;
N = 6)
116 (63–220;
N = 9)
134 (46–212; N = 6) 105.5 (46–165;
N = 2)
134 (63–212;
N = 4)
TP, elevated, median (range),
patients
107.5 (46–220;
N = 18)
60 (46–182;
N = 7)
112 (56–220;
N = 11)
103 (46–212; N = 7) 105.5 (46–165;
N = 2)
103 (56–212;
N = 5)
Glucose, normal, all LPs 85% (17/20) 80% (4/5) 86.7% (13/15) 100% (14/14) 100% (4/4) 100% (10/10)
Glucose, normal, all LPs, including
LPs classified as “normal”
93.9% (46/49) 92.9% (13/14) 94.3% (33/35) 100% (33/33) 100% (11/11) 100% (22/22)
Lactate, normal, all LPs 100% (7/7) 100% (1/1) 100% (6/6) 100% (7/7) 100% (1/1) 100% (6/6)
Lactate, normal, all LPs, including
LPs classified as “normal”
100% (35/35) 100% (10/10) 100% (25/25) 100% (24/24) 100% (8/8) 100% (16/16)
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Interestingly, MDS was associated with tuberculosis in
three of seven children with available data (3 × exposure
to adults with tuberculosis, including two cases with
strongly positive Mantoux skin test): two of African des-
cent and one described as “coloured”.
Other parameters
Link’s IgG index was positive in two additional, OCB-
negative patients. However, Link’s index has been shown
to be prone to false-positive results in patients with
blood–CSF barrier (BCB) dysfunction, due to the use of
a linear instead of a hyperbolic reference curve, and is
therefore no longer considered a reliable marker of
intrathecal IgG synthesis [22]. Indeed, in both cases high
TP CSF levels (165 and 103mg/dL) were noted indicat-
ing possible BCB dysfunction (albumin ratios not re-
ported). In consequence, the validity and relevance of
IgG index elevation remains unknown in these cases.
A slightly elevated γGF was noted in 2 patients (13.8%
and 14%, respectively; upper reference limit 13%), in-
cluding one of the OCB-positive patients, while γGF was
normal in 11 further LPs. In common with the IgG
index, γGF is an unreliable and thus obsolete marker of
intrathecal IgG synthesis. Data on IgG CSF/serum ratios
and Reibergrams, two better established markers of
intrathecal IgG synthesis, were reported in no patients
and only one patient (demonstrating absence of IgG syn-
thesis), respectively.
CSF MBP concentrations were measured in four pa-
tients and were elevated in three of them (207 ng/ml
[normal < 4] in one, not specified in the remainder).
This contrasts with mean CSF MBP levels of 8.2 ng/ml
in monosymptomatic and 22.3 ng/ml (elevated in 95%)
in polysymptomatic MS in a reference study [21].
Serum AQP4-IgG antibodies were reported in two
cases and were negative in both [23]. MOG-IgG was re-
ported in none. CSF opening pressure was measured
during 12 LPs in 11 patients and was elevated in two; in
these cases, the opening pressure was 280 and 510
mmH2O, respectively.
CSF findings in Schilder’s original case
For the sake of completeness, it should not go unmen-
tioned that Schilder’s index patient also underwent LP.
Overall, four CSF samples were obtained within 3
months. The CSF WCC was normal in the first sample
(although the sample was analysed only 24 h after LP)
taken 1 day after admission and 8 weeks after symptoms
started, was slightly elevated at day 15 (“5-8 cells per
field of view”), not assessed in the third sample and nor-
mal at day 70 despite most severe neurological deterior-
ation. TP was tested only in the second sample and was
slightly elevated. The CSF opening pressure was assessed
on the occasion of the second (200 mmH2O), third
(350 mmH2O) and fourth puncture (“Liquor unter
starkem Druck” [CSF under strong pressure]). While
the Wassermann reaction (a test indicating a possible
history of syphilis) was positive in the serum at ad-
mission, it was—after treatment with arsphenamine
(salvarsan) for suspected neurosyphilis—negative twice
in the CSF. However, when the CSF was tested using
Stern’s modified Wassermann test, it was positive.
Clinical and paraclinical findings in the OCB-positive
subgroup
In seven of the nine OCB-positive patients, the disease
had started during childhood or adolescence (at ages 5,
7.5, 9, 10, 12.5, 15 and 17 years) and in two during adult-
hood (at ages 18 and 24 years). The sex ratio (m:f ) was
1:3.5 and thus slightly higher than that in the total co-
hort (1:1.13). At last follow-up, one patient had experi-
enced only one attack (median follow-up, 4 years since
onset) with almost complete recovery, while six patients
had experienced at least two attacks (follow-up period 8
months, 19 months, > 19months, 2 years, 4 years and 8
years), with complete recovery in one, almost complete
recovery in three and fatal outcome in the remaining
two, who died during a tonic-clonic seizure and of pneu-
monia following severe neurological deterioration, re-
spectively. In two other patients, the disease took a
progressive course resulting in severe aphasia, cognitive
deficits and paresis after two years in one of them and
leading to death after 3.25 years in the other. ALD was
not formally excluded by VLCFA measurements in 5/9
cases (as stated above, after exclusion of patients not
tested for VLCFA, only 17% [4/24] were OCB positive).
However, all of those five patients were females, which
renders ALD unlikely. Moreover, adrenal function tests
were normal in two (and, in addition, adrenal autopsy in
one of them). In one of the two patients with no VLCFA
or adrenal test results available, the favourable outcome
with complete recovery argues against ALD; in the other,
at least basic plasma cortisol values and urinary
17-ketosteroids were tested and found to be normal. No
information on OCB patterns [22, 24] was given. CSF
WCC were reported in four and were elevated in two
(1 × “slightly elevated”, 1 × 32 cells/μl), with cytology re-
vealing lymphocytes (2 ×) and monocytes (1 ×); in two
other patients, CSF was reported to be “(otherwise) nor-
mal”, suggesting that WCC were normal. CSF TP was el-
evated in three of six patients (no data in two). Six of
the nine OCB-positive patients met the current diagnos-
tic criteria for relapsing–remitting MS (RRMS), one for
primary progressive MS [25]; a further patient presented
with a focal seizure half a year after first presentation
but showed no new lesion; and one patient had experi-
enced visual loss 3 years before diagnosis, but the infor-
mation about that episode was not sufficient to decide
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whether the criteria for RRMS were met. As a limitation,
it should be stressed that clinical data were sparse in
some reports, leaving some doubt regarding the exact
clinical course. In one OCB-positive case, the spinal cord
was involved as well. CSF MBP concentrations were
measured in one patient and were elevated. In seven
cases, histological data from biopsy (4 ×) or autopsy
(3 ×) samples were available; the findings were generally
compatible with a diagnosis of MDS. However, sparing
of U-fibers as noted in Schilder’s index case (but rare in
classic MS) was mentioned only in three of the
OCB-positive cases and was incomplete in two of them
(“rarely spared”; “U fibers involved in some areas”). No
exact data on the patients’ genetic background were
given: one was from Brazil (“dark-skinned”), one from
Morocco, one from Turkey, one from the USA and five
cases were reported by European-based centres (2 × Spain,
1 ×Germany, 1 ×Hungary, 1 × Italy). All LPs demonstrating
positive OCBs were performed between 1983 and 2003.
Discussion
Schilder’s myelinoclastic diffuse sclerosis (MDS), Devic’s
neuromyelitis optica (NMO) and Balo’s concentric scler-
osis (BCS) have all been described as “variants of MS”
for many decades. However, research performed over
the past two decades has cast serious doubt on the trad-
itional idea of MS being a homogeneous disease with a
number of clinicoradiological “variants”:
1. The demonstration of substantial histopathological
as well as immunological differences among
biopsied or autopsied patients with
clinicoradiologically defined bona fide MS ('pattern
1 MS', characterized by T cell and macrophage
infiltration, vs. 'pattern 2 MS', defined by additional
antibody and complement deposition, suggesting a
contribution of humoral mechanisms to disease
pathology, vs. 'pattern 3 MS', characterized by distal
oligodendrogliopathy with dysregulated myelin
protein expression and oligodendrocyte apoptosis,
still occuring on an inflammatory background) has
reintroduced the idea of immunopathogenetic
heterogeneity among patients with inflammatory
CNS demyelination [8, 26, 27].
2. AQP4-IgG-positive NMO has been convincingly
shown to be distinct from MS with regard to
pathogenesis, prognosis and optimum treatment
and—after a short period of disbelief and debates
between “lumpers and splitters” [28]—is now
considered a disease entity in its own right by
virtually all experts in the field.
3. MOG-IgG-positive encephalomyelitis (EM), which
shares substantial clinical overlap with both MS and
NMOSD, has also recently been shown to be an
immunologically distinct entity in its own right [29].
4. The recent identification of novel autoantibodies
against, for example, glial fibrillary acidic protein
(GFAP) [30] or the flotillin-1/2 heterocomplex [31]
in patients with CNS demyelination and reports on
demyelination in patients with anti-N-methyl-D-as-
partate receptor (NMDAR) encephalitis [32] have the
potential to further challenge the idea of MS as an
immunologically homogeneous disease in the future.
5. Finally, recent studies [33, 34] suggesting substantial
differences between MS and BCS in regard to both
radiological and histopathological presentation and
immunopathology have meanwhile also cast doubt
on the concept of BCS being a “variant of MS”.
In the present study, we demonstrate significant differ-
ences in CSF pathology between MS and MDS. Our find-
ings suggest that MS and MDS may be immunologically
distinct entities in most cases. Most strikingly, only 26% of
all patients diagnosed with MDS and only 17% of those
with a normal VLCFA test had OCBs. The fact that no
significant difference in the frequency of OCBs was noted
between 'historic' and more recent MDS patients, with
only a single case of OCB-positive MDS reported since
2003, widely rules out the possibility that lower assay sen-
sitivity in the past played a major role. The low frequency
of OCBs in MDS is in stark contrast to MS, in which
OCBs are considered a diagnostic hallmark. In addition,
we also found a significant difference between MS and
MDS with regard to the frequency of CSF pleocytosis. Fi-
nally, in many cases, CSF TP concentrations in MDS were
much higher than typically seen in MS.
We have already demonstrated that CSF profiles differ
significantly between MS and NMOSD [2, 3], MS and
BCS [33], MS and MOG-EM [10, 11, 35, 36] and between
biopsied/autopsied patients with suspected MS and
so-called pattern 1 brain lesions on the one hand and pa-
tients with so-called pattern 2 or 3 brain lesions on the
other [8] (Fig. 1). Given these differences in CSF path-
ology, which include discrepancies in hallmark features of
MS, it seems likely that NMOSD, BCS, MOG-EM and
MDS are entities immunologically distinct from MS in the
majority of cases. In the future, therefore, we recommend
abstaining from generally referring to NMO, BCS,
MOG-EM and MDS as “variants of MS”—a wording still
found in many neurological textbooks and in many review
articles on demyelinating diseases of the CNS. While
those disorders seem all to be inflammatory in nature and
to result in primary (as in MS and MOG-EM) or second-
ary (as in NMOSD and possibly BCS) demyelination, they
may not share a common immunopathogenesis.
Correct classification and differentiation of diseases is of
the utmost importance when it comes to clinical trials.
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Treatment recommendations in MS are based on large
phase III studies that probably included, as suggested by
prevalence, mainly patients with conventional MS. It is a
priori unknown whether the treatments found to be ef-
fective in such studies are equally effective (or effective at
all) in demyelinating disorders that share clinical features
but are pathogenetically distinct. The recent reclassifica-
tion of NMOSD as a discrete disease distinct from MS has
prompted studies that have reviewed treatment outcome
in NMOSD and in fact have revealed substantial differ-
ences in therapy response and optimum treatment be-
tween the two conditions: interferon beta and a number
of other MS drugs have been found to be probably inef-
fective or even detrimental in NMOSD [37] (while others,
such as B-cell depleting drugs, may be effective in both
disorders), and preliminary studies indicate that the same
may hold true for MOG-EM [10, 35].
Currently, there is no evidence-based therapy for
MDS. However, several case reports suggest that (high--
dose) steroid treatment may be effective. Other treat-
ments such as IVIG or rituximab have been tried in
single patients only, with no definite data on efficacy be-
ing available. The use of immunomodulatory drugs ap-
proved for the treatment of MS may be considered in
selected patients, e.g. in patients with suspected MDS
but later conversion to definite MS, especially if
OCB-positive, and in borderline cases suggestive of ei-
ther MDS or MS. That said, more data are certainly
needed before any definite recommendations on the
treatment of MDS can be made.
Historical perspective
From a historical perspective, it is interesting to learn
that Eugène Devic (1858–1930), the eponym of Devic’s
disease [38], i.e. NMO, Joseph Baló (1895–1979), ep-
onym of Balo’s disease, i.e. BCS, and Paul Schilder, ep-
onym of Schilder’s disease, i.e. MDS, were all rather
hesitant in classifying the conditions they encountered
in their patients as MS. However, the opinion of later
authors who had a broader audience finally prevailed.
While Devic and his pupil Fernand Gault (1873–1936)
had underlined in 1894 that lesion morphology in NMO
differs substantially from that in MS [39], most text-
books of the 20th century would hold the view that
NMO was a “variant of MS”, an opinion that can be
traced back at least to the 1930s. Lord Brain (1895–
1966), long-time editor of Brain and principal author of
Brain’s Diseases of the Nervous System, the standard
textbook of its time, stated in a widely cited 1930 review
article on disseminated sclerosis that “The clinical and
pathological differences between neuromyelitis optica
and disseminated sclerosis appear to be differences of
acuteness and intensity only (…) [currently] there seems
no justification for separating them” [40]. Nowadays,
NMO (or at least AQP4-IgG-positive NMOSD) is recog-
nized as a disease entity in its own right by virtually all
experts in the field [37, 41–43]. Similarly, Baló had be-
lieved his cases to represent a “disease [that] differs from
multiple sclerosis” as well as from Marburg’s “acute MS”
and Schilder’s “encephalitis periaxialis diffusa”, and
which he proposed to term “leuko-encephalitis periaxia-
lis concentrica” [44]. However, he could not prevent
BCS later being defined as a “variant of MS” by some of
the most authoritative textbooks right up to the modern
day. Likewise, Schilder concluded in his 1912 article that
the differences in clinical presentation were “hinreichend
ausgeprägt, um wenigstens vorläufig die Encephalitis
[periaxialis] diffusa der multiplen Sklerose als selbständiges
Fig. 1 Frequency of CSF-restricted OCBs in patients with adult MS (N = 276) [18], pediatric MS (N=136) [16], MDS (N = 35; present study), VLCFA-
negative MDS (N = 24; present study), BCS (N = 146) [32], NMOSD (N = 144) [3] and MOG-EM (N = 45) [10, 11, 34, 35]. AQP4+ aquaporin-4-IgG-positive,
AQP4− aquaporin-4-IgG-negative, BCS Baló’s concentric sclerosis, HQ-MRI high-quality MRI subgroup (see the “Results” section for details), MDS
myelinoclastic diffuse sclerosis, MOG-EM myelin oligodendrocyte glycoprotein antibody-positive encephalomyelitis, MS multiple sclerosis, NMOSD
neuromyelitis optica spectrum disorders, VLCFA− subgroup tested for very long-chain fatty acids (normal in all)
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Krankheitsbild gegenüber zu stellen [pronounced enough to
allow, for the time being, contrasting encephalitis diffusa
with multiple sclerosis as a self-contained disease entity]”
[1], only to be contradicted later on by a figure as eminent
as Charles M. Poser (1923–2010), lead author of the 1983
diagnostic criteria for MS, who in 2004 [45] would
still maintain the view that there was “little doubt”
that MDS was “simply another form of MS” (see also
Poser's "revised classification of the inflammatory de-
myelinating diseases" in [45]). Based on OCB fre-
quency, we believe that this may not be correct, at
least in the majority of cases.
Readers interested in the history of neurology may ap-
preciate to learn that Poser and Bogaert, in their seminal
1956 article on MDS (in which they pointed out that the
cases described by Schilder in 1913 [46] and 1924 [47]
rather represented instances of leukodystrophy and sub-
acute sclerosing encephalitis) classified Devic’s NMO as
a variant of Schilder’s MDS [48], thereby further contrib-
uting to nosological confusion. The only patient with
MDS so far tested for serum AQP4-IgG, a highly specific
marker of NMO, was negative for that marker [23] (a
second patient was negative for CSF AQP4-IgG [49];
however, CSF is not the specimen of choice when it
comes to testing for AQP4-IgG [50]).
Further differences between MDS and MS
In addition to the significant differences in terms of oligo-
clonal IgG synthesis and cellular CSF immune response
described above, we would like to draw attention to sev-
eral further lines of evidence suggesting that MDS may
not be the same disease as MS, with special reference to
Schilder’s index case (a previously healthy 14-year-old pre-
pubescent girl with eight healthy siblings).
1. Differences in lesion size and distribution:
(a) While MS (“encephalomyelitis disseminata”) is typic-
ally characterized by a multitude of disseminated, more or
less circumscribed lesions, Schilder’s patient showed a
large contiguous demyelinating lesion affecting most of
the white matter of the right hemisphere and the entire
corpus callosum and even extending through the corpus
callosum to the white matter of the other hemisphere.
Schilder considered this difference highly significant (“ein
sehr wesentliche[r Unterschied] […] [zur] gewöhnlichen
Multiplen Sklerose”).
(b) MS frequently affects the spinal cord from earliest
stages on [51]. By contrast, spinal cord inflammation was
described in only a few of the patients diagnosed with MDS
in the present study (one of whom was positive for OCBs,
had a second attack and met the clinicoradiological criteria
for RRMS, which casts some doubt on the diagnosis). Spinal
cord lesions were also absent in Schilder’s index case, as
were lesions in the brainstem, cerebellum and medulla
oblongata, areas often affected in MS (“Am Kleinhirn, am
Hirnstamm und der Medulla oblongata bestehen patholo-
gische Veränderungen nicht. Auch Durchschnitte durch das
Rückenmark sind in keiner Weise auffällig”).
(c) Neuropathologic and neuroimaging studies have
demonstrated involvement of the basal ganglia and thal-
amus in patients with MS [52–55]. By contrast, the basal
ganglia were spared in Schilder’s case, as mentioned
thrice in his article: “[Der Prozess] greift nicht auf die
basalen Ganglien über […] macht an […] den großen
Ganglien halt […] die basalen Ganglien zeigten keine
Veränderungen”. As a limitation, the patient’s young age
could have played a role [56].
(d) While the cortex was almost completely spared in
Schilder’s patient despite the extensive damage in the
white matter, it is frequently affected in MS [57, 58]. The lat-
ter fact was already known to Schilder: “Es verschonen also
die Herde der multiplen Sklerose die Rinde nicht [lesions in
MS do not spare the cortex]”, as he stated with reference to
the findings of Otto Marburg (1874–1948) and Herrmann
Oppenheim (1857–1919). For the sake of completeness, it
should not go unmentioned that Schilder observed a single,
very small area of cortical damage. However, according to
Schilder, the lesion was placed at a locus typicus for cortical
insult after Bramann–Anton’s “Balkenstich”, an operation
performed in his patient exactly 3months prior to autopsy.
The operation was personally carried out by Friedrich Gustav
von Bramann (1854–1913), and Gabriel Anton (1858–1933),
in collaboration with whom the method had been developed,
proofread Schilder’s article before publication (as can be seen
from the acknowledgement), suggesting that Schilder’s hy-
pothesis in this regard was somewhat 'evidence-based'. Re-
garding that small cortical lesion, Schilder noted several
differences from MS lesions as well as from his patient’s large
white matter lesion: the process was markedly destructive
(“auffallend destruktiv”, “beträchtlich schwerer als die des
Marks”), also in the non-cystic parts, with non-preservation
of the axons, destruction of the neuronal bodies, strong pro-
liferation of small vessels and severe pial damage.
(e) Schilder stressed that the U-fibers were spared in
his patient (“macht an den Fibrae arcuatae halt”). This
is of interest in the light of recent studies demonstrating
absence of U-fiber lesions in 20/21 (95.2%) patients with
MOG-EM in a mixed adult (n = 15) and paediatric (n =
6) cohort [59, 60] as detected by MRI. Similarly, U-fiber
lesions were absent in 65/69 (94.2%) MOG-IgG-positive
patients in a paediatric cohort [61]. By contrast, U-fiber
lesions are frequently seen in MS, and juxtacortical le-
sions were included in both the 1997 Barkhof criteria for
MS and the McDonald criteria for MS. Of note, preser-
vation of the U-fibers has also been observed in patients
with hereditary leukodystrophies, including X-linked
ALD (at least until a far-advanced stage) and
small-vessel diseases [62, 63]. U-fibers differ from other
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myelinated fibers with regard to age of myelination,
myelin metabolism and turnover, and blood supply.
(f ) The sparing of cortex, basal ganglia and U-fibers
was explicitly considered by Schilder as a feature distin-
guishing his case from MS: “Eine derartige Elektivität
kommt bei der multiplen Sklerose nicht vor [such electiv-
ity does not occur in MS]”.
(g) Schilder noted demyelination also in the optic chi-
asm, which is affected only rarely in MS, but commonly
in AQP4-IgG-positive NMOSD [64]. However, this find-
ing may be of limited relevance, since Schilder could not
come to a definite conclusion as to whether the rela-
tively mild demyelination observed was primary or ra-
ther secondary due to compression caused by increased
brain pressure.
2. Differences in histopathology:
(a) While small cysts may occur also in MS, the strongly
cystic formation of parts of the white matter lesion in
Schilder’s case, to which he referred as “Mikrozysten”,
“Zysten”, “Hohlräume”, “Höhlenbildung”, “Zerfallshöhlen”
[i.e. microcysts, cysts, cavitations, necrotic cavitations]
and the structure of which he compared to honeycombs
(“eigenartig feinwabig gebautes Gewebe”), would be un-
usual. Schilder considered this difference most import-
ant: “Auf die Differenzen [zur MS] im histologischen Bild
habe ich ja bereits verwiesen. Es sind vorwiegend die
schweren degenerativen Erscheinungen am Gliagewebe.
Der makroskopische Ausdruck dieser Differenz ist die
Höhlenbildung” [I have already pointed out the differ-
ences [from MS] in histological presentation. These are
mainly the degenerative changes of the glial tissue. The
macroscopic equivalent of that difference is the cavita-
tion]. Interestingly, Poser gave a very similar descrip-
tion of lesion formation in a patient with MDS he had
personally seen. In that patient, surgical exploration
demonstrated “a firm mass made up of many micro-
cysts with the general appearance of a beehive”. Histo-
logically, the parenchyma around blood vessels “looked
spongy and showed multiple, much interstitial
edema-forming microcysts” [65]. Cystic structures were
also described in other patients diagnosed with MDS in
whom biopsy or autopsy were performed (e.g. [66–70]).
(b) In contrast to typical MS lesions, lymphocytes were
almost completely missing and plasma cells completely
missing in Schilder’s case, despite highly active disease lead-
ing to death after 5months. This applies to all areas of the
white matter lesion, including older and newer parts, the
surrounding tissue, the (possibly unrelated) small cortical
lesion and the pia mater. Even in the perivascular cuffs of
most vessels only very rarely (“nur ganz selten”) were cells
seen that could have been lymphocytes (although, alterna-
tively, these few cells could have been reduced körnchenzel-
len according to Schilder). It should not remain
unmentioned that Schilder also observed occasional small
veins with somewhat more pronounced lymphocytic infil-
tration (“etwas stärker ausgeprägter Lymphocyteninfiltra-
tion”), though again without any evidence of plasma cells.
However, he relativized that statement later in a summary
of his findings by describing lymphocytes as being
“außerordentlich selten [extraordinarily rare]”. Overall, he
attached special importance to the contrast between the
drastic tissue damage and the minor (“geringfügig”) degree
of vascular inflammation as being one of the main differ-
ences of his case from typical MS. Inflammatory infiltrates
were also absent in the demyelinated parts of the chiasm
and optic nerve, including the vessel sheaths. As a limita-
tion, plasma cells can be sparse in early-active MS lesions
and their numbers are believed to vary among patients [71].
Of note, complete absence of plasma cells, which are the
source of CSF-restricted OCBs, as well as sparing of the
cortex and basal ganglia, have also been reported in Mar-
burg’s acute 'variant of MS' [72]; in line with that finding,
the patient had neither OCBs nor quantitative evidence of
intrathecal IgG, immunoglobulin M (IgM) or immuno-
globulin A (IgA) synthesis. However, in contrast to
Schilder’s patient, patients with Marburg’s disease mostly
have multiple lesions and—often fatal—brainstem lesions
[72].
(c) Schilder mentioned a number of further circum-
stances he believed would argue in favour of his case be-
ing distinct from MS: markedly better preservation of
axons than in MS; more pronounced nuclear alterations
in glial cells; and more pronounced degradation of the
large glial cells by microglial cells than seen in MS.
3. Differences in associated infections:
(a) EBV has been involved in the pathogenesis of MS, with
virtually all patients with MS being positive for serum anti-
bodies against EBV [73, 74]. However, antibodies to EBV
were absent in all five published patients diagnosed with
MDS that were tested for that marker.
(b) Schilder’s patient as well as her mother showed a
positive Wassermann reaction, which occurs in (con-
genital) syphilis, neurotuberculosis and systemic lupus
erythematosus. Unfortunately, most later cases of MDS
were not examined for syphilis (or results were not re-
ported). Exposure to tuberculosis and/or a positive Man-
toux test has indeed been described in 3/7 MDS patients
with available data. Both neurosyphilis and neurotuber-
culosis are not normally associated with MS but are dif-
ferential diagnoses of MS.
(c) Intrathecally produced polyclonal antiviral anti-
bodies, which are probably part of non-specific by-
stander activation of intrathecal B cells, distinguish MS
from other autoimmune disorders of the CNS: A posi-
tive intrathecal IgG immune response against measles,
rubella and zoster virus (the so-called MRZ reaction,
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defined by positive antibody indices against at least two
of those three viral agents) is the marker with the cur-
rently highest positive likelihood ratio for MS and has
been shown to be detectable in around 70% of patients
with MS [4, 18]. Intrathecal production of antibodies to
measles (with or without concomitant antibodies
against rubella and zoster virus) has been demonstrated
in up to 86% of patients with MS and is the most com-
mon intrathecal antiviral immune response in MS, both
in adults and in children [18]. However, all MDS pa-
tients tested had a negative MRZ reaction, and no indi-
cation for intrathecal IgG synthesis of antibodies
against measles could be found in the present cohort.
4. Differences in clinical presentation and outcome:
(a) Schilder’s patient died after 5months of continuous
deterioration. Her symptoms included, among others, se-
vere psychiatric and neuropsychological symptoms and
deficits (disorientation, dementia, apathy, somnolence, ar-
rest of thought, selective dyslexia, acoustic neglect,
pseudo-ophthalmoplegia), complete blindness, spastic
hemiplegia with facial paresis, paresis of the other leg,
neck stiffness and severe hyperpathia. In addition, signs of
increased intracranial pressure (increased CSF opening
pressure [up to 350 mmH2O], headache, nausea, repeat
vomiting and, possibly, bilateral stauungspapille) were
noted. Such a fulminant course is atypical for classic MS.
Increased CSF opening pressure, which does not typically
occur in MS, was also reported in some of the MDS cases
evaluated for the present study (see the “Results” section
for details).
(b) Definitive classification of the visual disturbances in
Schilder’s case is difficult. Initially, temporal pallor indi-
cated bilateral optic neuritis. In addition, prominent papil-
ledema (up to + 5 dpt) was apparent in both eyes,
indicating either papillitis or stauungspapille (i.e. a choked
optic disk due to increased intracranial pressure [ICP]).
Histologically, some degree of demyelination was noted in
the chiasm and intracranial optic nerve. However, the pa-
tient also exhibited signs and symptoms of cortical blind-
ness (visual anosognosia, persisting light reaction), in line
with demyelination affecting virtually the complete occipi-
tal lobe. Bilateral optic neuritis leading to complete blind-
ness within a few days is very uncommon in MS.
However, it is a common feature of both MOG-EM and
AQP4-IgG-positive NMOSD [10, 36]. Schilder also
considered remarkable the fact that signs of optic nerve
atrophy were seen just 11 days after onset, which is not
typical for MS. Irrespective of whether the papilledema in-
dicated increased ICP (stauungspapille) or inflammatory
papillitis—Schilder himself remained equivocal in that re-
gard, since the extracranial portion of the optic nerve was
not examined histologically—or both, papilledema would
be atypical in MS, which is not usually associated with
increased intracranial pressure and mostly affects the
retrobulbar parts of the optic nerves. Interestingly, papilli-
tis was recently shown to be common in patients positive
for MOG-IgG [10], a marker not yet tested in patients di-
agnosed with MDS.
Limitations and strengths
We count the high number of LPs analysed (given the
low prevalence of the disease) among the strengths of
this study, together with the fact that our results were
both highly significant and robust when retested in a
subgroup with particularly high diagnostic certainty, i.e.
after exclusion of patients not tested for VLCFA (see the
“Results” section for details). With no differences be-
tween historic and recent patients in terms of OCB fre-
quency and only very few patients having been treated at
the time of LP, we can also broadly rule out an effect of
assay sensitivity or treatment. Moreover, the very high
rate of OCBs in classic MS is not a new finding linked
to modern techniques but was reported in studies per-
formed as long ago as some of the earliest MDS studies
with available OCB data analysed here. Finally, so far an
effect of immunotherapies on OCB positivity has been
shown only for natalizumab [75, 76], which was not used
in any of the patients analysed for this study.
On the other hand, the retrospective nature of our
study and the fact that the patients included in the ana-
lysis were seen at many different centres are potential
limitations. Given the condition’s very low prevalence, how-
ever, it is impossible to perform a large prospective
single-centre study on MDS. Moreover, the study’s retro-
spective 'multicenter' setting reduced potential risks result-
ing from centre-specific selection bias, a problem inherent
to single-centre studies. Second, no CSF results were given
in several of the reports analysed for this study. This may
have introduced a bias towards cases with pathological CSF
findings. However, that would imply that our results actually
underestimate the lack of OCBs and pleocytosis in MDS
and would thus make our findings even more relevant.
The lack of generally accepted criteria for MDS or a
gold standard laboratory marker is another potential
limitation, which, however, cannot be avoided. By relying
on the diagnoses made by the reporting physicians and
providing a subgroup analysis of more recent cases, our
findings relate to MDS as it is currently understood and
diagnosed in clinical practice. In addition, we provide
subgroup analyses for those patients in whom ALD was
properly excluded in order to avoid any bias caused by
unwittingly including patients with the metabolic form
of MDS: OCBs were missing both in most patients with
MDS in which ALD was properly excluded and in most
patients with MDS in which ALD was not adequately
ruled out. Patients with a diagnosis of ALD were not in-
cluded at all.
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The present study considered exclusively patients with a
final diagnosis of MDS as made by the reporting authors.
This could be considered a strength but also a potential
limitation, since we may have overlooked further published
cases of true MDS in which the authors did not arrive at
the correct diagnosis. In 2009, Bacigaluppi and colleagues
retrospectively identified 10 additional patients with pos-
sible MDS, based on clinical and paraclinical presentation,
in whom the diagnosis of MDS was not made by the
reporting authors (and who were thus not included in the
present study) [77]. LP was performed in 9 of those 10 pa-
tients. It is reassuring that OCBs were absent in all of those
cases too, confirming our findings. OCB negativity in MDS
was also suggested by Tselis and Lisak in 2006, though
based on retrospective analysis of only 6 cases [78].
While our data suggest that MDS and MS are different
diseases in most instances, it is still possible that MS
presents as MDS in some cases. Indeed, a number of
similarities between MDS and MS exist: Both diseases
result in demyelinating lesions of the CNS (though the
spinal cord and the cerebral cortex—sites commonly af-
fected in MS—seem to be mostly spared in MDS); both
diseases may take a relapsing (e.g. [79]) or chronic pro-
gressive course (though monophasic disease seems to be
common in MDS, but not in MS); perivascular lympho-
cyte infiltration (as seen in MS) has been reported in
single cases (e.g. [80]); and large lesions (though not typ-
ically extending through the corpus callosum as reported
in MDS) have been described to occur also in a small
subset of patients with otherwise typical MS. It is thus
theoretically possible that some patients classified as
MDS had in fact MS, especially in the OCB-positive sub-
group: At least six of the nine OCB-positive patients had
experienced a second relapse, and seven met the current
diagnostic criteria for MS (6 × RRMS, 1 × PPMS). More-
over, one of the OCB-positive patients additionally had
spinal cord lesions, which are usually considered atypical
for MDS, and at least one had optic neuritis, a common
manifestation of MS. Finally, in 2003, Sastre-Garriga and
colleagues indeed published an OCB-positive case of
“Schilder-like onset” in otherwise typical MS [81]. That
patient developed a new contrast-enhancing lesion after
6months and left optic neuritis after 7months. The final
diagnosis was “clinically definite MS”. On the other hand,
the observation time was quite long in most of the
OCB-positive cases (up to 8 years; ≥ 2 years in 5/7; no data
in 1), so that occurrence of new lesions, as usually seen in
MS, should have been noted. In fact, a new lesion was ob-
served in only two out of nine OCB-positive “MDS” pa-
tients. Moreover, the description of beehive-like lesion
formation in Poser’s OCB-positive case matches Schilder’s
original description better than that of typical MS lesions. It
is therefore conceivable that OCB may indeed occur in a
small subset of patient with true MDS. That would be
similar to AQP4-IgG-positive NMOSD, BCS and
MOG-EM, conditions in which OCBs are detectable in
only 20–30% [2], 18–34% [33] and 12–13% [10] of cases,
respectively.
Testing of patients with MDS for CSF-restricted OCBs,
MRZ reaction and serum EBV-IgG might be helpful in
differentiating MS and MDS. Given that Schilder’s original
patient as well as the patient’s mother exhibited a positive
Wassermann reaction and that MDS was associated with
tuberculosis in some cases, those planning future studies
in MDS should consider inclusion of testing for syphilis
and tuberculosis in the diagnostic panel. Retrospective
serological studies on MOG-IgG and AQP4-IgG in pa-
tients with MDS are currently being performed; however,
testing for these markers in future patients with MDS is
highly recommended.
The present study focused on immunological parameters
routinely tested in patients with MS and MDS. Further im-
munological studies are now required to investigate the
differences between MDS and MS in greater detail in terms
of immunopathogenesis. Similarly, more endeavours are
needed to better understand the relationship of MDS to
other acquired demyelinating syndromes such as ADEM,
MOG-EM and Marburg’s disease.
Conclusion
This retrospective study strongly suggests that MS and
MDS are immunologically distinct conditions by demon-
strating highly significant differences regarding both the
humoral and the cellular arm of the intrathecal immune
response. We recommend hesitation in classifying MDS
as a “variant of MS” in the future; rather MDS should be
considered an entity immunologically distinct from clas-
sic MS in most cases. Our findings are not only of noso-
logical relevance but also harbour potential therapeutic
implications. Further studies are now needed to improve
understanding of the differences in pathogenesis be-
tween MDS and MS suggested by our findings, as well
as of potential differences in optimum treatment.
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